US 12,275,792 B2
Antigen-binding proteins that activate the leptin receptor
Jesper Gromada, Scarsdale, NY (US); Panayiotis Stevis, West Orange, NJ (US); and Judith Altarejos, Chappaqua, NY (US)
Assigned to REGENERON PHARMACEUTICALS, INC., Tarrytown, NY (US)
Filed by Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed on Nov. 30, 2021, as Appl. No. 17/539,034.
Application 17/539,034 is a division of application No. 16/593,761, filed on Oct. 4, 2019, abandoned.
Application 16/593,761 is a division of application No. 16/007,812, filed on Jun. 13, 2018, granted, now 10,618,968, issued on Apr. 14, 2020.
Application 16/007,812 is a division of application No. 15/290,967, filed on Oct. 11, 2016, granted, now 10,023,644, issued on Jul. 17, 2018.
Claims priority of provisional application 62/240,021, filed on Oct. 12, 2015.
Claims priority of provisional application 62/359,757, filed on Jul. 8, 2016.
Claims priority of provisional application 62/375,495, filed on Aug. 16, 2016.
Claims priority of provisional application 62/393,143, filed on Sep. 12, 2016.
Prior Publication US 2022/0112293 A1, Apr. 14, 2022
Int. Cl. A61K 39/00 (2006.01); A61K 39/395 (2006.01); C07K 16/00 (2006.01); C07K 16/28 (2006.01)
CPC C07K 16/2869 (2013.01) [A61K 39/395 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/565 (2013.01); C07K 2317/75 (2013.01); C07K 2317/92 (2013.01)] 14 Claims
 
1. A method for treating a disease or condition associated with or caused by leptin deficiency or leptin resistance, which is familial partial lipodystrophy, the method comprising administering, to a patient in need thereof, a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and an antibody or antigen-binding fragment thereof that comprises:
a light chain variable region that comprises the complementarity determining regions (CDRs) of a light chain variable region that comprises the amino acid sequence set forth in SEQ ID NO: 10; and
a heavy chain variable region that comprises the CDRs of a heavy chain variable region that comprises the amino acid sequence set forth in SEQ ID NO: 2, SEQ ID NO: 26 or SEQ ID NO: 34.